UNSPSC 51412009: Linsidomine

This classification denotes a vasodilating agent and nitric oxide-releasing compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5O5U71P6VQ. European Medicines Agency schedules Linsidomine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08524MIG. Linsidomine generally arises in the molecular formula C6H10N4O2.

UNSPSC 51412009 Linsidomine, a Commodity code, encompasses emergency and critical-care medications supplied to state and local health and safety agencies, particularly fire rescue and emergency medical services. State and local governments procure specific injectable medications—vasopressors, cardiac agents, and antiarrhythmics—through competitive sealed bids and cooperative purchasing agreements, with vendors required to meet strict expiration dating, cold-chain compliance, and hazmat documentation standards. Issuing bodies include city fire departments and rescue services, state health and human services commissions managing pharmacy benefit programs, and multistate cooperative purchasing alliances administering agreements for state and local facilities. The City of Tampa Fire Rescue and the Texas Health and Human Services Commission represent recent activity in this space, with purchasing departments handling both direct-supply procurement and pharmacy program coordination.

Recent opportunities appear concentrated in Florida, Texas, and the Upper Midwest. The City of Tampa Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, seeking 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine, and 1,020 units of Diltiazem with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the award included a 5 percent Small Local Business Enterprise bid discount and required nine-month minimum shelf life from acceptance, with OSHA hazmat documentation and WCAG accessibility compliance. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802) on January 20, 2026, closing March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with evaluation weighted 75 percent on price competitiveness and 25 percent split across fixed pricing, administrative compliance, and EDI capability; contract term is two years with optional extensions. The Texas HHS Commission issued an RFI (HHS0017013) posted April 3, 2026, to assess vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling intent toward downstream formal RFP solicitation.